Work Here?
Overview
Vizgen operates in spatial genomics and sells the MERSCOPE imaging platform for high-resolution single-cell and spatial multiomics analyses to map gene expression within tissue context. It uses MERFISH chemistry to collect sensitive, spatially resolved RNA data, enabling study of cellular and subcellular tissue organization. In addition to hardware, Vizgen offers a Gene Panel Design Portal for building custom gene panels and VPT for cell segmentation that defines cell boundaries and outputs single-cell data. Its goal is to help research institutions obtain precise spatial gene-expression data to understand tissue architecture and accelerate discoveries in cancer and other diseases.
About Vizgen
Industries
Data & Analytics
Enterprise Software
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series E
Total Funding
$184.2M
Headquarters
Cambridge, Massachusetts
Founded
2019
Simplify's Take
What believers are saying
- $48M Series funding from ARCH Venture Partners enables global expansion and manufacturing scale-up[3]
- Patent portfolio strength: U.S. Patent 11,959,075 and PTAB denial of 10x IPR validate MERFISH IP leadership[3]
- Certified Service Provider program democratizes access to spatial genomics, expanding addressable market beyond direct sales[3]
What critics are saying
- 10x Genomics Xenium captures market share through aggressive pricing, eroding MERSCOPE premium positioning[3]
- Nanostring CosMx detects 6,000+ genes with simpler workflow, diverting high-plex customers from MERSCOPE Ultra[3]
- Harvard license termination risk amid litigation escalation enables 10x to launch direct MERFISH clones[3]
What makes Vizgen unique
- MERFISH 2.0 achieves nanometer-precision subcellular resolution with unmatched multiplexing across 1,000+ RNA targets[1][2]
- MERSCOPE Ultra processes 3 cm² tissue at double imaging speed, enabling high-throughput spatial multiomics at scale[5]
- Hamamatsu partnership integrates MoxiePlex mIF imaging with InSituPlex assays for end-to-end multiplex biomarker workflows[3]
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$184.2M
Meets
Industry Average
Funded Over
4 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↓ -2%Vizgen raises $48M in funding. Vizgen, a Waltham, MA-based spatial multi-omics company, raised $48M in funding. The round was led by ARCH Venture Partners and M Ventures and Northpond Ventures with participation from existing investors. The company intends to use the funds to expand its ability to serve researchers globally, and scale manufacturing operations. Co-founded by Xiaowei Zhuang, PhD, Professor David Walt, PhD, and Jeffrey Moffitt, PhD, and led by CEO Rob Carson, Vizgen leverages technologies that enable researchers to improve deep insights into human biology and disease. Through its MERFISH 2.0 technology and MERSCOPE Platform for in situ single-cell spatial genomics and its InSituPlex protein assays and AI-driven STARVUE spatial image analysis technology, the company delivers tools that enable researchers to uncover deep insights into human biology and achieve solutions in understanding mechanisms of complex diseases, including neurodegenerative disorders and cancer. MERFISH and InSituPlex are for research use only. Vizgen has R&D and lab services operations in nearby Cambridge.
Waltham, Mass. – January 8, 2026 – Vizgen, Inc., a leader in spatial multi-omics, today announced the closing of a $48 million financing. The financing was led by ARCH Venture Partners and co-led by M Ventures...
CAMBRIDGE, Mass., May 29, 2025 /PRNewswire/ -- Vizgen, Inc., a life sciences company advancing spatial multi-omics, today announced a strategic partnership with Hamamatsu Photonics K.K., a global leader in optical imaging technology. This collaboration integrates Hamamatsu's MoxiePlex™ multiplex immunofluorescence (mIF) imaging system with Vizgen's pathology-grade reagent and assay portfolio, delivering a seamless end-to-end solution designed to bring multiplexed biomarker detection into new translational and clinical research applications.The partnership aims to eliminate common barriers in multiplex assay development − streamlining validation, simplifying workflow integration, and enabling researchers to focus on acquiring high-fidelity biological insights. By combining cutting-edge imaging with highly adaptable multiplex assays, this partnership will offer a joint solution designed to scale with customer needs and facilitate the transition from research to clinical impact."Partnerships like this are essential to push the field of multiplex immunofluorescence forward and bring advanced imaging technologies closer to clinical relevance," said Toshimichi Ishizuka, Director of the Systems Division at Hamamatsu Photonics. "By integrating our hardware with Ultivue's versatile chemistry, we're offering a solution that's not only powerful but practical for real-world use."The MoxiePlex™ platform offers up to 9-color imaging with high throughput capacity with up to 60 slides per run − designed for high-volume laboratories. Vizgen's InSituPlex® assays enable rapid deployment of custom research panels with pre-validated biomarkers, minimizing time-to-data while maintaining exceptional specificity and reproducibility. Together, these technologies empower research labs to build and refine multiplex assays with greater speed and confidence.Vizgen and Hamamatsu plan to combine their expertise through validated InSituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multi-site deployments for translational research and clinical research applications
Vizgen announces end of litigation with 10x Genomics and Harvard University.
Christian Uhrich, Investment Director at M Ventures, joins Vizgen Board of Directors; Chad Brown joins the company as Chief Commercial Officer
There are no jobs for Vizgen right now.
Find jobs on Simplify and start your career today
About Vizgen
Industries
Data & Analytics
Enterprise Software
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series E
Total Funding
$184.2M
Headquarters
Cambridge, Massachusetts
Founded
2019
There are no jobs for Vizgen right now.
Find jobs on Simplify and start your career today